Hidradenitis suppurativa is a dermatological disease that affects areas of apocrine sweat glands such as buttocks, area under the breast, under the arms, inner the thighs. It is also known as acne inversa. The disease is characterized by development of follicular occlusions that lead to progressive scarring. Early symptoms of hidradenitis suppurativa include erythema and local hidradenitis, which become painful in later stages. Hidradenitis suppurativa arises as a result of hormonal imbalance, friction from clothing, and sweating. According to an article published in Current Dermatology Reports in 2014; smoking, obesity, and genetic factors are also responsible for causing the disease. The disease is more prevalent in women as compared to men, with a ratio of 3:1. Globally, the disease affects around 1% of the population. The disease is uncommon but not rare. It can occur at any age, but it is most common at the age of 20–30 years.
Based on treatment, the global hidradenitis suppurativa market has been segmented into medications, laser treatment, surgery, and others. The medications segment has been sub-segmented into biologics, antibiotics, hormonal therapy, immunosuppressive drugs, zinc supplements, retinoids, pain medication, and others. Currently, only one FDA-approved therapeutic drug i.e. adalimumab (Humira) is available for treatment of hidradenitis suppurativa. Several antibiotics, hormone therapy, and corticosteroids are prescribed off-label. Treatment of hidradenitis suppurativa still remains a challenge for scientists worldwide. Surgical removal is also a preferred mode of treatment, but the disease may relapse in other areas. Research to develop drugs for the treatment of hidradenitis suppurativa is currently in progress. As of 2017, certain drugs are under clinical development such as brilacidin, CJM 112, and xilonix. Increase in the incidence of chronic inflammatory skin diseases, the large number of ongoing clinical trials, and introduction to new treatment options are factors likely to boost the hidradenitis suppurativa market during the forecast period. However, a weak pipeline has questioned growth of the market for hidradenitis suppurativa, as most of these trials are in phase II, indicating lesser chances of approval. This factor is projected to restrain the hidradenitis suppurativa market in the near future. In addition, high cost of therapy and associated side-effects are estimated to restrain the hidradenitis suppurativa market during the forecast period.
Based on skin conditions, the hidradenitis suppurativa market has been divided into pimples, boils, deep-acne, folliculitis, and others. The folliculitis segment has been sub-segmented into hot tub folliculitis (pseudomonas folliculitis), bacterial folliculitis, pityrosporum folliculitis, barber's itch (pseudofolliculitis barbae), and others. The deep-acne segment has been further divided into blackheads, cysts, and others. The boils segment has been sub-divided into pilondial cyst, carbuncle, cystic acne, and others.
In terms of geography, the global hidradenitis suppurativa market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America leads the global hidradenitis suppurativa market, followed by Europe. Growth of the market in North America is attributable to increase in the number of inflammatory skin conditions and the large number of ongoing clinical trials. Asia Pacific is an emerging market for hidradenitis suppurativa, due to increase in the prevalence of hidradenitis suppurativa in this region. Developing health care infrastructure and rising government expenditure on the health care industry are factors projected to boost the hidradenitis suppurativa market in Asia Pacific during the forecast period. However, factors such as low awareness among patients, high cost of therapy, and limited access to health care facilities restrain the hidradenitis suppurativa market in regions such as Middle East & Africa and Latin America.
Major players operating in the global hidradenitis suppurativa market include AbbVie Inc., AstraZeneca, Johnson & Johnson, Merck & Co., Inc., Allergan, Pfizer Inc., and GlaxoSmithKline plc.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.